231 related articles for article (PubMed ID: 26725095)
1. Increased expression of phosphatidylethanolamine-binding protein 4 (PEBP4) strongly associates with human gliomas grade.
Huang RQ; Shi DL; Huang W; Chen F; Lu YC
J Neurooncol; 2016 Apr; 127(2):235-42. PubMed ID: 26725095
[TBL] [Abstract][Full Text] [Related]
2. MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation.
Conti A; Romeo SG; Cama A; La Torre D; Barresi V; Pezzino G; Tomasello C; Cardali S; Angileri FF; Polito F; Ferlazzo G; Di Giorgio R; Germanò A; Aguennouz M
Tumour Biol; 2016 Oct; 37(10):14035-14048. PubMed ID: 27495233
[TBL] [Abstract][Full Text] [Related]
3. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M
J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of PEBP4 inhibits human glioma cell growth and invasive potential via ERK1/2 signaling pathway.
Huang RQ; Wang SQ; Zhu QB; Guo SC; Shi DL; Chen F; Fang YC; Chen R; Lu YC
Mol Carcinog; 2019 Jan; 58(1):135-143. PubMed ID: 30255656
[TBL] [Abstract][Full Text] [Related]
5. Slit2 and Robo1 expression as biomarkers for assessing prognosis in brain glioma patients.
Liu L; Li W; Geng S; Fang Y; Sun Z; Hu H; Liang Z; Yan Z
Surg Oncol; 2016 Dec; 25(4):405-410. PubMed ID: 27916173
[TBL] [Abstract][Full Text] [Related]
6. DDX3X Biomarker Correlates with Poor Survival in Human Gliomas.
Hueng DY; Tsai WC; Chiou HY; Feng SW; Lin C; Li YF; Huang LC; Lin MH
Int J Mol Sci; 2015 Jul; 16(7):15578-91. PubMed ID: 26184164
[TBL] [Abstract][Full Text] [Related]
7. Deregulated expression of cry1 and cry2 in human gliomas.
Luo Y; Wang F; Chen LA; Chen XW; Chen ZJ; Liu PF; li FF; Li CY; Liang W
Asian Pac J Cancer Prev; 2012; 13(11):5725-8. PubMed ID: 23317246
[TBL] [Abstract][Full Text] [Related]
8. Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Lin L; Wang G; Ming J; Meng X; Han B; Sun B; Cai J; Jiang C
Tumour Biol; 2016 Nov; 37(11):15333-15339. PubMed ID: 27704357
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Roundabout4 predicts poor prognosis of primary glioma patients via correlating with microvessel density.
Cai H; Xue Y; Liu W; Li Z; Hu Y; Li Z; Shang X; Liu Y
J Neurooncol; 2015 May; 123(1):161-9. PubMed ID: 25859844
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-203 down-regulation is associated with unfavorable prognosis in human glioma.
He J; Deng Y; Yang G; Xie W
J Surg Oncol; 2013 Aug; 108(2):121-5. PubMed ID: 23813496
[TBL] [Abstract][Full Text] [Related]
11. Expression level of human miR-34a correlates with glioma grade and prognosis.
Gao H; Zhao H; Xiang W
J Neurooncol; 2013 Jun; 113(2):221-8. PubMed ID: 23529798
[TBL] [Abstract][Full Text] [Related]
12. High expression of RAB43 predicts poor prognosis and is associated with epithelial-mesenchymal transition in gliomas.
Han MZ; Huang B; Chen AJ; Zhang X; Xu R; Wang J; Li XG
Oncol Rep; 2017 Feb; 37(2):903-912. PubMed ID: 28075478
[TBL] [Abstract][Full Text] [Related]
13. Kinesin family member 14 is a candidate prognostic marker for outcome of glioma patients.
Wang Q; Wang L; Li D; Deng J; Zhao Z; He S; Zhang Y; Tu Y
Cancer Epidemiol; 2013 Feb; 37(1):79-84. PubMed ID: 22999822
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of p42.3 in low- and high-grade gliomas.
Wan W; Xu X; Jia G; Li W; Wang J; Ren T; Wu Z; Zhang J; Zhang L; Lu Y
World J Surg Oncol; 2014 Jun; 12():185. PubMed ID: 24927751
[TBL] [Abstract][Full Text] [Related]
15. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.
Zeng J; Zhang XK; Chen HD; Zhong ZH; Wu QL; Lin SX
Oncotarget; 2016 Feb; 7(8):8944-55. PubMed ID: 26771840
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma.
Pang C; Guan Y; Zhao K; Chen L; Bao Y; Cui R; Li G; Wang Y
Int J Clin Exp Pathol; 2015; 8(5):4943-52. PubMed ID: 26191187
[TBL] [Abstract][Full Text] [Related]
17. The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients.
Yang X; Li D; Cheng S; Fan K; Sheng L; Zhang J; Feng B; Xu Z
Tumour Biol; 2014 Nov; 35(11):11091-5. PubMed ID: 25099618
[TBL] [Abstract][Full Text] [Related]
18. RIZ1: a potential tumor suppressor in glioma.
Zhang C; Zhu Q; He H; Jiang L; Qiang Q; Hu L; Hu G; Jiang Y; Ding X; Lu Y
BMC Cancer; 2015 Dec; 15():990. PubMed ID: 26690953
[TBL] [Abstract][Full Text] [Related]
19. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
Wu X; Wu F; Xu D; Zhang T
J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
